← Back to Search

Monoclonal Antibodies

APG777 for Eczema

Phase 2
Recruiting
Research Sponsored by Apogee Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Prior treatment with protocol-specified monoclonal antibodies (mAbs)
Has used systemic treatments (other than biologics) and/or phototherapies and/or laser therapy that could affect AD within 4 weeks prior to Baseline visit
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial will test a new medication called APG777 for people with moderate-to-severe Atopic Dermatitis. The study has two parts: Part A will test the safety and effectiveness of different dos

Who is the study for?
This trial is for people with moderate-to-severe Atopic Dermatitis (AD), commonly known as eczema. Participants will be involved in the study for up to 106 weeks, which includes different phases such as screening and treatment follow-ups. Details on specific inclusion or exclusion criteria are not provided.
What is being tested?
The trial is testing APG777 against a placebo to see if it's safe and effective for AD. It has two parts: Part A tests one induction dose regimen of APG777 and two maintenance regimens; Part B compares three dose regimens of APG777 with a placebo, including one maintenance regimen.
What are the potential side effects?
Specific side effects are not listed, but generally, clinical trials look out for any adverse reactions ranging from mild symptoms like itching or redness at the application site to more serious systemic effects.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have previously been treated with specific monoclonal antibodies.
Select...
I haven't used any systemic treatments, phototherapies, or laser therapy that could affect my condition in the last 4 weeks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: Part B: Maintenance Period: APG777Experimental Treatment1 Intervention
Participants will receive APG777 per protocol defined dosing regimen
Group II: Part B: Induction Period: APG777Experimental Treatment1 Intervention
Participants will receive APG777 in 1 of 3 regimens per protocol defined dosing regimen
Group III: Part A: Maintenance Period: APG777Experimental Treatment1 Intervention
Participants will receive 1 of 2 maintenance regimens of APG777 per protocol defined dosing regimen
Group IV: Part A: Induction Period: APG777Experimental Treatment1 Intervention
Participants will receive APG777 per protocol defined dosing regimen
Group V: Part B: Induction Period: PlaceboPlacebo Group1 Intervention
Participants will receive matching placebo injections per protocol defined dosing regimen
Group VI: Part A: Induction Period: PlaceboPlacebo Group1 Intervention
Participants will receive matching Placebo injections per protocol defined dosing regimen

Find a Location

Who is running the clinical trial?

Apogee Therapeutics, Inc.Lead Sponsor
~314 spots leftby Nov 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top